aXichem AB (publ) publishes Annual Report 2023
aXichem AB (publ), a developer of natural analogue industrial compounds, today publishes its
Annual Report 2023 in Swedish. An English translation will be available shortly.
The report can be accessed on the company´s website https://www.axichem.com/investor-relations/#financial-reports
The information was submitted, through the care of the contact person below, for publication on 29 May 2024, at 09:00 AM CET.
Company contact:
Torsten Helsing, CEO, aXichem AB
Phone: +46 706 863 355 Email: torsten.helsing@axichem.com
About aXichem
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio- enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.
More information is available at www.axichem.com.